New study demonstrates how lysosomal replacement enzymes may be improved by glycoengineering

With Weihua Tian and Zhang Yang as main drivers, Copenhagen Center for Glycomics recently published a study demonstrating that sugar structures may be optimized to improve drug function of lysosomal replacement enzyme in animal model of Fabry Disease. The optimized sugar structure or design called LAGD (Long-Acting GlycoDesign) was developed in collaboration with the spin-out company GlycoDisplay, that will use the LAGD to develop improved replacement enzymes for Fabry and other devastating lysosomal storage diseases. The paper with the title "The glycosylation design space for recombinant lysosomal replacement enzymes produced in CHO cells" was published in Nature Communications on April 30 2019.

Read the original publication in Nature Communications, and interviews with the authors published in Berlingske Business, Medwatch and by the UCPH Health Science News